The maker of blockbuster appetite-suppressing drugs Mounjaro and Zepbound is seeking to end a regulatory designation that has ...

Eli Lilly and Novo Nordisk have been top stocks for investors who are bullish on the weight loss market. However, fellow ...

Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular ...

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...

Forget Mounjaro: 1 Reason Investors Should Love Eli Lilly Stock Even More (Hint: I'm Not Talking About Zepbound) ...

Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to ...

Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster ...

U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's ...

Key Takeaways Eli Lilly is investing $1.8 billion to expand production in Ireland of its Alzheimer's treatment and ...

Weight loss drugs are likely to stay in demand for a long time judging by the obesity trend as shown by latest CDC data ...

The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis.

Eli Lilly's new insulin data —Sanofi x Regeneron autoimmune drugs —Gilead's new AI partnership Get the full rundown here: ...